bemarituzumab + SOX + nivolumab

**Bemarituzumab + SOX + nivolumab** is a combination regimen under clinical investigation for the first-line treatment of advanced gastric and gastroesophageal junction cancer, specifically in patients whose tumors overexpress FGFR2b. The regimen combines: - **Bemarituzumab**, a monoclonal antibody that targets and inhibits FGFR2b, a receptor involved in tumor growth and progression. - **SOX**, a chemotherapy backbone consisting of S-1 (an oral fluoropyrimidine derivative) and oxaliplatin (a platinum-based chemotherapeutic), both of which interfere with DNA synthesis and repair, leading to cancer cell death. - **Nivolumab**, a monoclonal antibody immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor, enhances T-cell mediated anti-tumor immune responses. This combination aims to achieve additive anti-tumor effects by targeting cancer cells directly (chemotherapy and FGFR2b inhibition) and harnessing the immune system (immune checkpoint blockade with nivolumab). The regimen is currently evaluated for safety, tolerability, and efficacy (e.g., objective response rate, survival outcomes) in clinical trials for untreated advanced gastric and gastroesophageal junction cancers with FGFR2b overexpression[2][7].

Other names

bemarituzumab + S-1 + oxaliplatin + nivolumab